<DOC>
	<DOCNO>NCT03005782</DOCNO>
	<brief_summary>In dose escalation : safety PK In dose expansion : response rate</brief_summary>
	<brief_title>Study REGN3767 ( Anti-LAG-3 ) With Without REGN2810 ( Anti-PD1 ) Advanced Cancers</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Men woman â‰¥18 year age Dose escalation cohort : Patients histologically cytologically confirm diagnosis malignancy ( include lymphoma ) demonstrate progression tumor available therapy likely convey clinical benefit AND previously treat PD1/PDL1 inhibitor . These patient require measurable disease Dose expansion cohort : Patients histologically cytologically confirm diagnosis 1 specify tumor measurable disease per RECIST 1.1 Lugano criterion . Some patient may previously treat PD1 PDL1 inhibitor Eastern Cooperative Oncology Group performance status 0 1 Adequate organ bone marrow function Prior treatment LAG3 target biologic small molecule Radiation therapy within 2 week prior randomization recover baseline AE due radiation Untreated active central nervous system metastasis Ongoing recent ( within 5 year ) evidence significant autoimmune disease Corticosteroid therapy ( &gt; 10 mg prednisone/day equivalent ) within 1 week prior first dose study drug Myocardial infarction within 6 month Documented allergic acute hypersensitivity reaction attribute antibody treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>